KZIA is having a wonderful dayPrice and volume action. This tells me something is cooking and there is a potential to go up higher. Stop loss should be around 0.32. Target 0.90 area.Longby findalphas0
KZIA Good Risk:Reward RatioKZIA had a very large runup, and a pullback to Higher Low at 0.5637. Expecting a bounce from this level, to scale out of position up above @$1.02; $1.24 and $1.33 levels (Prior swing highs of the leg down). With the minimum risk:reward being 10:1, it is too good of opportunity to miss. Longby ADmytrenko22
KZIA bullishKZIA bullish into that .29 - .26 buy zone in AUGUST lots of volume into this pullback shares being shortedLongby opcondour1
Short KZIAA short at 1.00 to 0.8934 with the necessary risk management will bring a 10.92% returnShortby KyleUK0
KZIA 30min TF Scalptest Kazia Therapeutics Ltd. is a clinical stage oncology company It engages in the pharmaceutical research and development business. The company was founded by Graham Edmund Kelly in March 1994 and is headquartered in Sydney, Australia.Longby TheCryptoChartWhisperer2
$KZIA looks good for a parabolic runLooks extremely bullish - definitely watching this stock. If price drops to $9, definitely a buy. Australia based firm has some key cancer drugs in the pipeline. (1) Price above Kumo (2) Future Kumo bullish (3) Senkou span A & B with positive slope (4) Both Tenkan Sen & Kijun Sen have +ve slopes (5) Chikou Span above the price & free to go up (6) ADX > 25Longby arindamsen11
It already started spinning upTHIS stock is in a resistance right now, the price reaction in this resistance will depend on the continuity of this emerging trendLongby FranzSavantTrader1
MONDAY MANIAIt's another week full of expectations. How would this go about? Would really be watching this closely.by Piplott122
KZIA: Higher price rejection after gap upHigher price rejection after spike and gap up. May retrace and fill gap. If confirmed PT1 = 5,82 PT2 = 4,52 (for gap fill)Shortby LeLaf220
FDA Grants RPDD to Paxalisib for DIPGUS FDA Grants Rare Pediatric Disease Designation (RPDD) to Paxalisib for DIPG Key Points With RPDD granted, Kazia may now be eligible to receive a 'rare pediatric disease priority review voucher' (PRV) if paxalisib is approved for DIPG A PRV grants the holder an expedited six-month review of a new drug application by FDA. PRVs can be sold to other companies and have historically commanded prices between US$68 million and US$350 million RPDD has been awarded following positive emerging preclinical data in DIPG, and with initial clinical efficacy data expected in 2H CY2020; positive clinical data may substantially enhance likelihood of a potential future PRV The FDA's RPDD program is intended to advance the development of drugs and biologics for certain serious and life-threatening rare pediatric diseases by providing incentives to industry. Most significant among these incentives is the potential access a priority review voucher at the time of a marketing authorization for the rare paediatric disease. RPDD may be granted to drugs in development for diseases which primarily affect children (under the age of 18 years), have an incidence of less than 200,000 new cases per annum in the United States, and which are serious or life-threatening. In effect, the PRV shortens the FDA review period for a future marketing application of any drug from 12 months to 6 months. finance.yahoo.com by AlenCiken0
KZIA Leading Diagonal Wave 5 beginsHello, What is KZIA? Kazia Therapeutics Limited, an oncology-focused biotechnology company, develops anti-cancer drugs. Its lead development candidate is GDC-0084, a small molecule, brain-penetrant inhibitor of the PI3K/AKT/mTOR pathway, which is developed as a potential therapy for glioblastoma. The company is also developing Cantrixil, which is being developed for the treatment of ovarian cancer and is in hospitals across Australia and the United States under an Investigational New Drug application. Kazia Therapeutics Limited has collaboration agreements St Jude Childrens Hospital; Dana-Farber Cancer Institute; Alliance for Clinical Trials in Oncology; Memorial Sloan Kettering Cancer Centre; and University of Newcastle. The company was formerly known as Novogen Limited and changed its name to Kazia Therapeutics Limited in November 2017. Kazia Therapeutics Limited was founded in 1994 and is headquartered in Sydney, Australia. News My Thoughts For You Click on the link "News" and you will find that the outcome is showing positive results which will affect the price. Good Luck, Cheers! Be sure to comment, follow, like, and check out my profile for more trade ideas! Longby keifer3315
Bullish future for KZIA$KZIA Positive Overall Survival in Glioblastoma Study Kazia expects to present further data in 2H CY2020 Sales in excess of US$ 1 billion per annum treatment for glioblastomaLongby Time_Oracle227
KAZIA Therapeutics Ltd Golden CrossCompany profile Kazia Therapeutics Ltd. engages in the pharmaceutical drug research and development. Its pipeline includes two clinical-stage drug development candidates such as GDC-0084, and Cantrixil. The company was founded by Graham Edmund Kelly in March 1994 and is headquartered in Sydney, Australia. by DEXWireNews16